Results
8553
Companies with a Future performance score of at least 3, ordered by Future performance score.
8,553 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
SKS | AU$2.17 | 3.3% | 689.1% | AU$243.2m | AU$2.15 | PE36.7x | E24.8% | 0.5% | Capital Goods | ||
MVW | NOK 8.85 | -2.2% | 2.2% | NOK 289.6m | NOK 11.70 | PS15.1x | E71.7% | n/a | Materials | ||
INIT | SEK 7.00 | -2.1% | -22.0% | SEK 392.9m | SEK 22.50 | PB16.2x | E31.7% | n/a | Pharmaceuticals & Biotech | ||
CADLR | NOK 57.30 | -4.2% | 19.5% | NOK 20.1b | NOK 81.86 | PE187.4x | E70.9% | n/a | Capital Goods | ||
AFISH | NOK 69.50 | -7.3% | 15.8% | NOK 2.2b | NOK 83.50 | PE67.5x | E66.5% | n/a | Food, Beverage & Tobacco | ||
GAU | CA$1.54 | -12.0% | 30.5% | CA$401.0m | CA$3.47 | PS1.7x | E107.8% | n/a | Materials | ||
GUINNESS | ₦70.00 | 7.7% | -1.1% | ₦153.3b | ₦72.64 | PS0.4x | E116.7% | 0% | Food, Beverage & Tobacco | ||
ELABS | NOK 10.90 | 5.8% | -34.4% | NOK 1.1b | NOK 19.00 | PS12.3x | E121.1% | n/a | Software | ||
RMDA | ج.م3.26 | -1.2% | 71.6% | ج.م4.9b | ج.م5.02 | PE18.4x | E30.7% | 2.1% | Pharmaceuticals & Biotech | ||
WAYS | SEK 15.62 | -4.3% | -45.2% | SEK 126.0m | SEK 36.50 | PS1x | E113.3% | 0% | Tech | ||
RHM | €692.40 | 7.4% | 107.4% | €30.1b | €725.20 | PE43.9x | E29.9% | 0.8% | Capital Goods | ||
FWRY | ج.م8.41 | 0.7% | 47.5% | ج.م28.6b | ج.م12.45 | PE23.1x | E27.4% | n/a | Diversified Financials | ||
ACE | SEK 3.16 | 8.2% | -49.4% | SEK 303.2m | SEK 8.25 | PB2.8x | E47.2% | n/a | Pharmaceuticals & Biotech | ||
MBTN | CHF 2.73 | 23.9% | -96.6% | CHF 84.2m | CHF 6.03 | PS1x | E109.3% | n/a | Semiconductors | ||
ICOP | €8.20 | -1.2% | n/a | €226.6m | €9.80 | PE44.9x | E49.2% | n/a | Capital Goods | ||
PHM | €79.35 | 6.4% | 106.5% | €1.4b | €83.20 | PE2220.6x | E56.2% | 0.8% | Pharmaceuticals & Biotech | ||
AGP | €6.26 | -4.0% | -30.4% | €108.4m | €12.85 | PE16x | E22.1% | n/a | Capital Goods | ||
NEWBRY | SEK 3.54 | 4.1% | -23.9% | SEK 85.9m | SEK 8.00 | PS2.3x | E130.0% | n/a | Pharmaceuticals & Biotech | ||
PRL | CA$36.59 | 6.6% | 114.1% | CA$1.4b | CA$45.20 | PE22.8x | E38.9% | 1.6% | Diversified Financials | ||
EXEL | US$36.20 | 1.5% | 60.1% | US$10.3b | US$35.61 | PE22.1x | E20.5% | n/a | Pharmaceuticals & Biotech | ||
ARES | US$191.32 | 6.8% | 62.8% | US$59.9b | US$188.92 | PE89.3x | E38.4% | 1.9% | Diversified Financials | ||
ZVRA | US$8.05 | 4.5% | 35.5% | US$429.7m | US$20.63 | PS17.5x | E57.8% | n/a | Pharmaceuticals & Biotech | ||
ONON | US$57.98 | 6.4% | 109.1% | US$18.6b | US$60.77 | PE133.5x | E29.7% | n/a | Consumer Durables | ||
MX1 | AU$0.083 | 3.8% | -21.0% | AU$49.4m | AU$0.19 | PS3.2x | E68.7% | n/a | Healthcare |